313 related articles for article (PubMed ID: 16365730)
1. False-positive FDG PET uptake--the role of PET/CT.
Rosenbaum SJ; Lind T; Antoch G; Bockisch A
Eur Radiol; 2006 May; 16(5):1054-65. PubMed ID: 16365730
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Combined PET-CT in the head and neck: part 1. Physiologic, altered physiologic, and artifactual FDG uptake.
Blodgett TM; Fukui MB; Snyderman CH; Branstetter BF; McCook BM; Townsend DW; Meltzer CC
Radiographics; 2005; 25(4):897-912. PubMed ID: 16009814
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
5. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
Kumar R; Hawkins RA; Yeh BM; Wang ZJ
Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
[TBL] [Abstract][Full Text] [Related]
6. Pediatric FDG PET/CT: physiologic uptake, normal variants, and benign conditions.
Shammas A; Lim R; Charron M
Radiographics; 2009; 29(5):1467-86. PubMed ID: 19755606
[TBL] [Abstract][Full Text] [Related]
7. False-positive uptake on 2-[¹⁸F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in oncological imaging.
Culverwell AD; Scarsbrook AF; Chowdhury FU
Clin Radiol; 2011 Apr; 66(4):366-82. PubMed ID: 21356398
[TBL] [Abstract][Full Text] [Related]
8. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
9. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
10. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake.
Kostakoglu L; Hardoff R; Mirtcheva R; Goldsmith SJ
Radiographics; 2004; 24(5):1411-31. PubMed ID: 15371617
[TBL] [Abstract][Full Text] [Related]
11. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
12. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
Choi JY; Lee KS; Kim HJ; Shim YM; Kwon OJ; Park K; Baek CH; Chung JH; Lee KH; Kim BT
J Nucl Med; 2006 Apr; 47(4):609-15. PubMed ID: 16595494
[TBL] [Abstract][Full Text] [Related]
13. Whole-body PET/CT: spectrum of physiological variants, artifacts and interpretative pitfalls in cancer patients.
Gorospe L; Raman S; Echeveste J; Avril N; Herrero Y; Herna Ndez S
Nucl Med Commun; 2005 Aug; 26(8):671-87. PubMed ID: 16000985
[TBL] [Abstract][Full Text] [Related]
14. [Positron-emission tomography/computed tomography: artifacts and pitfalls in cancer patients].
Gorospe Sarasúa L; Echeveste Aizpurúa J; Raman S
Radiologia; 2006; 48(4):189-204. PubMed ID: 17058646
[TBL] [Abstract][Full Text] [Related]
15. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
16. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion.
Schöder H; Yeung HW; Gonen M; Kraus D; Larson SM
Radiology; 2004 Apr; 231(1):65-72. PubMed ID: 14990824
[TBL] [Abstract][Full Text] [Related]
17. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study.
Buchs NC; Bühler L; Bucher P; Willi JP; Frossard JL; Roth AD; Addeo P; Rosset A; Terraz S; Becker CD; Ratib O; Morel P
J Gastroenterol Hepatol; 2011 Apr; 26(4):657-62. PubMed ID: 21155879
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET/CT in differentiating malignant from benign origins of obstructive jaundice.
Wang SB; Wu HB; Wang QS; Zhou WL; Tian Y; Ji YH; Lv L
Hepatobiliary Pancreat Dis Int; 2015 Oct; 14(5):516-22. PubMed ID: 26459728
[TBL] [Abstract][Full Text] [Related]
19. PET and PET-CT. State of the art and future prospects.
Fanti S; Franchi R; Battista G; Monetti N; Canini R
Radiol Med; 2005; 110(1-2):1-15. PubMed ID: 16163136
[TBL] [Abstract][Full Text] [Related]
20. False-positive 18-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) scans mimicking malignancies.
Yasar Z; Acat M; Onaran H; H Dincer E; Cetinkaya E; A Korkmaz N; Ozgül A
Med Glas (Zenica); 2015 Feb; 12(1):40-6. PubMed ID: 25669335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
